Company: HURA
Filing Date: 2025-10-31
Form Type: 424B3
Source: 0001193125-25-260933
Chunk: 3

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-10-31
Form: 424B3
Chunk 3
---
 interest in U.S patents owned by the Company related to its ImmuneFxTMtechnology platform.

In addition, in connection with each loan advance made pursuant to the Loan Agreement, the Company will issue to the Lender a warrant to purchase shares of the Company’s common stock (each, a “Lender Warrant”) equal to 10% of the applicable loan advance divided by the exercise price, which shall be equal to the Nasdaq Official Closing price on such date of issuance, subject to adjustment in certain circumstances. On the date of the Initial Advance, the Company issued a Lender Warrant to the Lender to purchase up to 65,217 shares of common stock. Each Lender Warrant will be immediately exercisable and will expire on the date that is two years from the date of issuance.

The foregoing descriptions of the Loan Agreement and the Lender Warrant, are summary in nature and are each qualified by reference to the full text of each, copies of which are attached as Exhibits 10.1 and 10.2 to this Current Report on Form 8-K.

Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

The information set forth under Item 1.01 above is hereby incorporated by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No

10.1 Secured Promissory Note and Loan Agreement

10.2 Form of Lender Warrant

104 Cover Page Interactive Data File (embedded within the inline XBRL document)

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

| Date: | October 31, 2025 | By: | TUHURA BIOSCIENCES, INC.       
 /s/ Dan Dearborn               |
|:------|:-----------------|:----|:-------------------------------|
|       |                  |     | Name: Dan Dearborn             
 Title: Chief Financial Officer |

Exhibit 10.1

THIS NOTE HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR UNDER THE SECURITIES LAWS OF ANY STATES IN THE UNITED STATES. THIS NOTE IS SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AND RESALE AND MAY NOT BE TRANSFERRED OR RESOLD EXCEPT AS PERMITTED